Dual PI3K/mTOR inhibitors such as dactolisib (BEZ235), apitolisib (GDC-0980), gedatolisib (PF-05212384), bimiralisib (PQR309), paxalisib (GDC-0084), and voxtalisib (SAR245409, XL765) have shown substantial anticancer efficacy in various tumor xenografts (9, 115–117). This evidence concerns the gene PIK3CB and neoplasm.